Results 31 to 40 of about 1,810,595 (288)

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Journal for ImmunoTherapy of Cancer, 2019
Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh, Joycelyn Lee, Gloria Chan, Cheng Ean Chee, Su Pin Choo   +4 more
doaj   +1 more source

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Frontiers in Cell and Developmental Biology, 2020
Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon, Youngmi Kim, Hyun Suk Jung, Dooil Jeoung   +3 more
doaj   +1 more source

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition

JEADV Clinical Practice, 2023
The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer, Thomas Gan, Jochen Gaa, Tilo Biedermann, Christian Posch   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Neurotoxicity

Current Neuropharmacology, 2021
: Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with varying incidence and symptom complexity ...
Zhao, Zhiyi, Zhang, Chunlin, Zhou, Lian, Dong, Pan, Shi, Lei   +4 more
openaire   +3 more sources

Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu, 2019
With the gradually in-depth research of immune checkpoint, the checkpoint inhibitors, such as programmed death-1(PD-1) inhibitors, programmed death–ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated protein-4(CTLA-4) inhibitors, had made ...
LI Xiangmin, FAN Zaiwen
doaj   +1 more source

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu, 2021
Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers.
YU Lin, LI Guangping, ZHOU Changyu, FU Huaying   +3 more
doaj   +1 more source

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Cancer Biology & Medicine, 2015
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis, Richard Skelton, Lei Zheng   +2 more
doaj   +1 more source

The role of immune checkpoint inhibitors in prostate cancer [PDF]

, 2018
Introduction Prostate cancer (PC) is the most commonly diagnosed malignant tumour and the third cause of cancer deaths among men in Europe. The treatment of early-stage PC is very effective and in many cases allows achievement of a complete cure, whereas
Marek Hus, Katarzyna Chyl-Surdacka, Gabriel Surdacki, Surdacki, G., Szudy-Szczyrek, A., Chyl-Surdacka, K., Gorący, A., Hus, M., Aneta Gorący, Aneta Szudy-Szczyrek   +9 more
core   +1 more source

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Journal of Immunology Research, 2020
Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis, Ayman Sayyed, Mohammed Darweesh, Panayotis Kaloyannidis, Hani Al Hashmi   +4 more
doaj   +1 more source

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source